semaglutide patent expiration canada approves generic from Dr. Reddy's, a G7 first enabled by Novo Nordisk's lapsed CAD$250 Indian generics undercut Wegovy by

Trained in pharmacology and cosmetic science and fellowship-certified in aesthetic medicine, she designs evidence-based weight-loss and body-sculpting programs for high-achieving women who demand results.

H., Upadhyay, N., van Hest, N., Kirk, M., Spaepen, E., Zimner-Rapuch, S., Annemans, L., & Bays, H

CTO-46 transferred additional cases, including potential Mounjaro actions, to the MDL. December 9, 2025: Eli Lilly filed its answer to the amended master complaint, while Novo Nordisk responded for its GLP-1 products, as Mounjaro suits advance amid failure-to-warn claims

Expanded Zepbound approval

Current Urology Reports, 24 (11), 515525.